NEW YORK--(BUSINESS WIRE)--Gentium S.p.A. (Nasdaq: GENT) announced the presentation of six of preclinical abstracts and posters supporting key mechanism for of Defibrotide in the regulation, inhibition and protection of key regulatory proteins effecting human cancers, diabetic nephropathy and endothelial damage. The data was presented at the International Society on Thrombosis and Haemostasis in Geneva, Switzerland being held from July 6 – 12, 2007.
